Gathering the Stakeholder's Perspective: Experiences and Opportunities in Rare Genetic Disease Research.
22q11.2 deletion syndrome
copy number variations (CNVs)
neurodevelopmental psychiatric disorders (NPDs)
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
07 01 2023
07 01 2023
Historique:
received:
03
11
2022
revised:
22
12
2022
accepted:
03
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Research participant feedback is rarely collected; therefore, investigators have limited understanding regarding stakeholders' (affected individuals/caregivers) motivation to participate. Members of the Genes to Mental Health Network (G2MH) surveyed stakeholders affected by copy number variants (CNVs) regarding perceived incentives for study participation, opinions concerning research priorities, and the necessity for future funding. Respondents were also asked about feelings of preparedness, research burden, and satisfaction with research study participation. Modified validated surveys were used to assess stakeholders´ views across three domains: (1) Research Study Enrollment, Retainment, Withdrawal, and Future Participation; (2) Overall Research Experience, Burden, and Preparedness; (3) Research Priorities and Obstacles. Top box score analyses were performed. A total of 704 stakeholders´ responded from 29 countries representing 55 CNVs. The top reasons for initial participation in the research included reasons related to education and altruism. The top reasons for leaving a research study included treatment risks and side effects. The importance of sharing research findings and laboratory results with stakeholders was underscored by participants. Most stakeholders reported positive research experiences. This study provides important insight into how individuals and families affected with a rare CNV feel toward research participation and their overall experience in rare disease research. There are clear targets for areas of improvement for study teams, although many stakeholders reported positive research experiences. Key findings from this international survey may help advance collaborative research and improve the experience of participants, investigators, and other stakeholders moving forward.
Sections du résumé
BACKGROUND
Research participant feedback is rarely collected; therefore, investigators have limited understanding regarding stakeholders' (affected individuals/caregivers) motivation to participate. Members of the Genes to Mental Health Network (G2MH) surveyed stakeholders affected by copy number variants (CNVs) regarding perceived incentives for study participation, opinions concerning research priorities, and the necessity for future funding. Respondents were also asked about feelings of preparedness, research burden, and satisfaction with research study participation.
METHODS
Modified validated surveys were used to assess stakeholders´ views across three domains: (1) Research Study Enrollment, Retainment, Withdrawal, and Future Participation; (2) Overall Research Experience, Burden, and Preparedness; (3) Research Priorities and Obstacles. Top box score analyses were performed.
RESULTS
A total of 704 stakeholders´ responded from 29 countries representing 55 CNVs. The top reasons for initial participation in the research included reasons related to education and altruism. The top reasons for leaving a research study included treatment risks and side effects. The importance of sharing research findings and laboratory results with stakeholders was underscored by participants. Most stakeholders reported positive research experiences.
CONCLUSIONS
This study provides important insight into how individuals and families affected with a rare CNV feel toward research participation and their overall experience in rare disease research. There are clear targets for areas of improvement for study teams, although many stakeholders reported positive research experiences. Key findings from this international survey may help advance collaborative research and improve the experience of participants, investigators, and other stakeholders moving forward.
Identifiants
pubmed: 36672911
pii: genes14010169
doi: 10.3390/genes14010169
pmc: PMC9859499
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NICHD NIH HHS
ID : R13 HD103471
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH119705
Pays : United States
Organisme : NIH HHS
ID : MH 1U01MH119738
Pays : United States
Références
Medicine (Baltimore). 2011 Jan;90(1):1-18
pubmed: 21200182
Cell. 2012 Mar 16;148(6):1223-41
pubmed: 22424231
CMAJ Open. 2021 Aug 17;9(3):E802-E809
pubmed: 34404688
N Engl J Med. 2013 Dec 5;369(23):2179-81
pubmed: 24304050
Control Clin Trials. 1985 Jun;6(2):156-67
pubmed: 4006489
J Clin Transl Sci. 2020 Mar 06;4(4):317-322
pubmed: 33244412
Hum Mol Genet. 2015 Oct 15;24(R1):R45-9
pubmed: 26130694
Clin Transl Sci. 2011 Dec;4(6):403-13
pubmed: 22212221
Trials. 2016 Oct 6;17(1):483
pubmed: 27716378
AJOB Empir Bioeth. 2014;5(4):14-21
pubmed: 25419533
Curr Opin Genet Dev. 2021 Jun;68:57-63
pubmed: 33752146
Clin Transl Sci. 2014 Dec;7(6):430-40
pubmed: 24842076
Nat Rev Dis Primers. 2015 Nov 19;1:15071
pubmed: 27189754
Clin Res (Alex). 2016 Jun;30(3):42-47
pubmed: 27390769
JAMA Psychiatry. 2020 Dec 1;77(12):1276-1285
pubmed: 32697297
Trends Genet. 2009 Dec;25(12):536-44
pubmed: 19910074
Clin Transl Sci. 2012 Dec;5(6):452-60
pubmed: 23253666
J Med Life. 2009 Apr-Jun;2(2):227-31
pubmed: 20108545
Hum Genomics. 2021 Mar 12;15(1):16
pubmed: 33712057
JAMA Psychiatry. 2022 Mar 01;79(3):250-259
pubmed: 35080590
Health Serv Res. 2010 Aug;45(4):1024-40
pubmed: 20528990
Int J Qual Health Care. 1998 Aug;10(4):319-30
pubmed: 9835248